EGFR has been the most extensively studied with respect to activation compared with the other ERBB receptors, so our discussion will focus EGFR, but much of the following is consistent for all the ...

The IPASS (Iressa Pan-Asia Study) is the first large randomized clinical trial that compared first-line EGFR TKI therapy with chemotherapy. 1 In this study, 1,217 Asian non-smokers or former light ...

“While we’re not yet at the point where we ... epidermal growth factor receptor (EGFR), a protein that helps cells grow and ...

Here, we show that mice overexpressing a dominant negative isoform of epidermal growth factor receptor (EGFR) were protected from renal lesions during chronic AngII infusion. Transforming growth ...

Interestingly, cancers that co-overexpress EGFR and HER2 have a worse clinical outcome than those overexpressing either receptor alone ... type (i.e., kinase domain mutations in lung cancer ...

It aims to treat cancers that occur from mutations of the epidermal growth factor receptor (EGFR ... a biotech stock to watch. At this point the stock is a highly speculative purchase, as both ...

Using microarrays to perform a genome-wide assessment of the receptor network, they found that EGFR and ErbB2 bind to proteins more promiscuously, and activate many more signaling pathways, as they ...